Century Therapeutics, Inc.
IPSCNASDAQHealthcare● Active
$2.19
+$0.07(+3.07%)
Market Cap$189154115
P/E Ratio—
52W High$3.04
52W Low$0.435
Century Therapeutics, Inc. (IPSC) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IPSC · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.01B) | ($0.13B) | ($0.14B) | ($0.13B) | ($0.10B) |
| Depreciation & Amort. | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Change in Working Capital | ($0.11B) | ($0.01B) | $0.01B | $0.12B | ($0.00B) |
| Net Cash from Operations | ($0.10B) | ($0.11B) | ($0.09B) | $0.01B | ($0.09B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.01B) | ($0.03B) | ($0.04B) |
| Purchases of Investments | ($0.05B) | ($0.12B) | ($0.21B) | ($0.25B) | ($0.33B) |
| Sales of Investments | ($0.05B) | $0.18B | $0.28B | $0.27B | $0.08B |
| Net Cash from Investing | $0.11B | $0.05B | $0.06B | ($0.01B) | ($0.30B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | ($0.01B) | $0.00B | $0.00B |
| Net Cash from Financing | $0.00B | $0.07B | ($0.01B) | $0.03B | $0.42B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.10B) | ($0.11B) | ($0.10B) | ($0.02B) | ($0.13B) |
| FCF Margin %(computed) | -95.93% | — | — | -318.37% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Century Therapeutics, Inc. data
About Century Therapeutics, Inc. (IPSC) Cash Flow Statement
Century Therapeutics, Inc. generated operating cash flow of ($0.10B) and free cash flow of ($0.10B) for 2025 — a FCF margin of -95.93%. Capital expenditure was ($0.00B).
Frequently asked questions
IPSC · 4 questionsCentury Therapeutics, Inc. generated free cash flow of ($0.10B) for 2025, up 5.0% year-over-year.
IPSC free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10